Chicago, IL (PRWEB) May 07, 2013
The birth control safety advocates at DrugRisks.com are announcing new information on the site for women using the oral contraceptives Yaz and Yasmin. The maker of the drugs, Bayer, has reported that sales have dropped more than 12% since last year*.
DrugRisks was created to increase the safety of patients taking popular prescription drugs like Yaz and Yasmin by providing the latest warnings, recalls, studies and legal news. Visitors can discover of others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from British Medical Journal** and FDA*** that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.
DrugRisks also noted that, with a growing number of patients filing a Yaz lawsuit alleging blood clot injuries, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
Bayer’s latest annual financial report shows the company has spent nearly $1 billion to settle around 4,800 claims alleging Yaz blood clots, and will continue to evaluate new claims for settlement on a case-by-case basis****.
Now, DrugRisks has learned that Bayer’s latest report to shareholders shows sales of Yaz and Yasmin have dropped 12.5% since last year, from 244 million to 206 million euros*.
Lawyers are still helping those affected file a claim. Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisks Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal MDL drug injury cases, DrugRisks cautions that patients should seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
Visit http://www.DrugRisks.com today for more information on the research, side effects and litigation news related to Yaz or Yasmin, or to speak with a lawyer.
*Bayer, 4/25/13; stockholders-newsletter-q1-2013.bayer.com/en/healthcare.aspx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****Bayer 2/28/13; annualreport2012.bayer.com/en/legal-risks.aspx